MMED day 1 121%

Mind Med is the first psychedelic company to IPO. Backed by big names from big brands, Shark Tank and Tom's Shoes and Canopy Growth. MMED has in its portfolio (1) psychedelic-derived drug for the treatment of opiate addiction made from indigenous African plant iboga used in religious rituals for thousands of years (2) LSD microdosing trials.

+
10x potential.

-
Most private sale investors have no lockup. Last week the company did a pre-IPO round at $0.33 for about 24M